drugset / Trial / NCT04849715
A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a Phase 3, double-blind, randomized, placebo-controlled, multicenter study of parsaclisib plus BR versus placebo plus BR as first-line treatment of participants with newly diagnosed MCL.
Timeline
- Start
- 2022-03-11
- Primary completion
- 2030-08-15
- Completion
- 2034-07-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Parsaclisib | Small molecule | — | Oral |
| Comparator | Bendamustine | Small molecule | — | Intravenous |
| Comparator | Rituximab | Monoclonal antibody | — | Intravenous |